Transactions

End-to-end transaction support covers every stage of an M&A or licensing deal from initial strategic positioning and enterprise valuation through process management, term sheet structuring, contract negotiation, regulatory and antitrust considerations, and signing and closing. Stonehaven Cozmix Group provides this support specifically for transactions involving Animal Health, Life Sciences, and adjacent healthcare companies, drawing on decades of combined commercial and legal experience inside the sector. The objective is to maximize value, manage risk, deliver a seamless process, and set up the post-closing organization for long-term success, not just to get a deal signed.

Sell-side advisory supports a company or its shareholders through the divestment of a business, asset, or subsidiary, typically including strategic positioning, preparing information memoranda and management presentations, identifying and qualifying potential buyers, running competitive auction processes, negotiating terms, and managing the deal through to closing. Buy-side advisory supports an acquirer through the acquisition of a target, typically including target identification, valuation, deal structuring, negotiation strategy, and process management. Both require deep transaction execution experience, but successful sell-side work additionally requires the ability to articulate a credible commercial story to multiple bidders simultaneously.

A competitive auction is a structured sale process in which multiple potential buyers are invited to submit bids over a defined timeline, aiming to maximize value through competitive tension. Auctions are typically used when a target has multiple credible buyers, when the seller wants to demonstrate a fair process to its board or shareholders, and when speed and price certainty are priorities. The process usually moves through stages: teaser distribution, non-binding offers, due diligence access, binding offers, and final negotiation. It requires careful management to maintain bidder engagement, protect confidentiality, and deliver the best terms.

Licensing deals grant rights to use intellectual property — patents, trademarks, regulatory dossiers, manufacturing know-how, marketing rights — typically in exchange for upfront payments, milestone payments, royalties, or a combination. In Animal Health and Life Sciences, licensing deals commonly take the form of in-licensing (acquiring rights to develop or commercialize an asset from another party), out-licensing (granting rights to a partner for specific geographies or applications), cross-licensing arrangements, and trademark or distribution licenses. Successful licensing structures balance commercial alignment, financial fairness, and the operational realities of how the licensed asset will be developed, manufactured, and sold over its lifecycle.

A carve-out is the sale of a business unit, product line, or asset that has been embedded within a larger corporate structure. Carve-outs are commercially attractive; they allow sellers to divest non-core assets and acquirers to buy focused businesses, but they are operationally complex because the carved-out entity typically depends on shared services, manufacturing capacity, IT systems, regulatory infrastructure, and personnel within the parent company. Successful carve-outs require careful business separation planning, well-structured transition services agreements (TSAs), and a clear roadmap for standing up the carved-out entity as a viable independent business after closing.

Alliances and partnerships cover structured commercial collaborations that fall short of a full acquisition or merger. Common forms in Animal Health and Life Sciences include joint ventures (where two or more parties create a shared entity to pursue a specific opportunity), co-commercialization agreements (where partners jointly market and sell a product, often splitting territories, customer segments, or channels), distribution partnerships, and research collaborations. These structures are valuable when an asset, geography, or capability is best pursued jointly, but they require careful design of governance, economics, decision rights, and exit provisions to avoid disputes and align long-term incentives.

Generic legal and transaction advisory firms can execute deal mechanics, but they often miss the sector-specific dynamics that drive transaction value — species-level demand patterns, veterinary channel economics, regulatory pathways across jurisdictions, generic erosion timelines, manufacturing and CMC considerations, and the operational realities of integrating Animal Health and Life Sciences businesses. Sector-specialist transaction advisors bring both legal and commercial fluency, which translates into better strategic positioning, sharper valuation, smarter deal structures, and fewer surprises after closing; this is why an increasing share of life sciences transactions involves specialist commercial-legal advisors alongside general counsel and investment banks.

Stonehaven Cozmix Group supports a wide range of clients on Animal Health and Life Sciences transactions: founders and family-owned businesses planning a first institutional sale, mid-cap and large corporate development teams pursuing acquisitions or divestments, Private Equity sponsors managing platform investments and exits, biotech and Animal Health innovators structuring licensing and partnership deals, and global Life Sciences groups managing complex carve-outs and multi-jurisdictional transactions. Engagements range from focused licensing structuring through end-to-end M&A advisory on multi-hundred-million-dollar deals.